Mechanism and Naming
CJC-1295 with DAC and modified GRF 1-29 or no-DAC are not interchangeable. The DAC form has published human pharmacokinetic data showing multi-day persistence; claims about the no-DAC form often rely on naming conventions, inference, or lower-confidence sources. Ipamorelin is a ghrelin-receptor agonist characterized primarily in preclinical pharmacology literature.
Evidence Comparison
| Record | Evidence point | Important limitation |
|---|---|---|
| CJC-1295 with DAC | Published human pharmacokinetic study | Does not establish an approved treatment protocol |
| CJC-1295 no-DAC / modified GRF 1-29 | Short-acting form discussed in research contexts | Suitable human pharmacokinetic evidence is limited |
| Ipamorelin | Selective ghrelin-receptor agonist in preclinical literature | Human pharmacokinetics and clinical use are not established |
| Combination | Mechanisms are theoretically complementary | Mechanistic rationale is not evidence of safety or efficacy |
Review the source-level profiles for CJC-1295 with DAC, CJC-1295 no-DAC, and ipamorelin.
Frequently Asked Questions
Which has the longer half-life?
CJC-1295 with DAC has the longest documented persistence of the three records. The exact human pharmacokinetic value for no-DAC and ipamorelin should not be treated as established from lower-confidence evidence.
Does complementary mechanism mean the combination works?
No. A mechanistic hypothesis does not establish clinical safety, efficacy, dose, or schedule.
Are these FDA-approved treatments?
No. These records should not be presented as approved treatment protocols.